Since all the studies available in the literature were conducted in North America or Europe, the results of percutaneous aortic valve replacement in Asia are unknown. We included 253 patients with severe aortic stenosis who received TAVI at 14 sites in Asia (Edwards Sapiens: 140 patients; Medtronic Core Valve: 113 patients). The success rate was<a href="https://solaci.org/en/2015/06/24/clinical-results-of-tavi-in-asia/" title="Read more" >...</a>
The objective was to evaluate the safety and efficacy of the Lotus Valve System to treat patients with severe aortic stenosis and high surgical risk. The study included 60 patients who received the device and were followed during 30 days. Mortality from all causes was 1.7% and the incidence of stroke was 8.6%, with half<a href="https://solaci.org/en/2015/06/24/reprise-ii-results-obtained-with-the-new-valve-according-to-varc-criteria/" title="Read more" >...</a>
Percutaneous aortic valve implantation ( TAVI ) recently demonstrated its superiority over medical treatment in patients with severe aortic stenosis and high surgical risk. Furthermore patients receiving TAVI showed a survival surgery equivalent to one year. This study included 471 patients with symptomatic severe aortic stenosis discarded of surgery due a very high risk. The<a href="https://solaci.org/en/2015/06/24/corevalve-extreme-risk-promising-results-with-corevalve-in-very-high-risk-patients/" title="Read more" >...</a>
Original title: Transcatheter Aortic Valve Replacement for Severe Symptomatic Aortic Stenosis Using a Repositionable Valve System. 30-Day Primary Endpoint Results From the REPRISE II Study. Reference: Ian T. Meredith AM et al. J Am Coll Cardiol 2014;64:1339–48. Transcatheter aortic valve replacement (TAVR) showed results comparable to those of surgery in patients at high surgical risk, but complications can<a href="https://solaci.org/en/2015/01/29/results-of-the-new-repositionable-and-retrievable-percutaneous-valve-system/" title="Read more" >...</a>
Original title: Impact of coronary artery disease on left ventricular ejection fraction recovery following transcatheter aortic valve implantation. Reference: Freixa X et al. Catheter Cardiovasc Interv. 2014;Epub ahead of print. This single center study analyzed data form 56 consecutive patients with severe aortic stenosis and LVEF of ≤ 50% undergoing TAVI (transcatheter aortic valve implantation) between March 2006<a href="https://solaci.org/en/2014/10/06/worse-post-tavi-ejection-fraction-recovery-in-coronary-artery-disease-patients-without-revascularization/" title="Read more" >...</a>
Original title: Early Regression of Severe Left Ventricular Hypertrophy After Transcatheter Aortic Valve Replacement Is Associated with Decreased Hospitalization. Reference: Brian Lindman, et al. JACC Cardiovasc Interv 2014;7:662-73. Left ventricular hypertrophy, defined by the increase of left ventricular mass, has long been associated to increased morbi-mortality in the context of different heart conditions. LV hypertrophy regression might<a href="https://solaci.org/en/2014/08/05/tavr-regression-of-left-ventricular-hypertrophy-decreases-re-hospitalization/" title="Read more" >...</a>
Original title: Predictive factors of early mortality after transcatheter aortic valve implantation: individual risk assessment using a simple escore. Reference: Heart. 2014 Apr 16. doi: 10.1136/heartjnl-2013-305314. Epub ahead of print. The decision to perform an intervention in symptomatic aortic stenosis must balance surgery or transcatheter aortic valve implantation (TAVI) risk. Factors associated with early mortality after TAVI<a href="https://solaci.org/en/2014/04/30/prognostic-factors-for-early-mortality-in-patients-undergoing-tavi-individual-risk-calculation-using-a-simple-score-derivative-analysis-from-france-ii-registry/" title="Read more" >...</a>
Original title: Transcatheter Aortic-Valve Replacement with a Self-Expanding Prosthesis. Reference: David H. Adams et al. N Engl J Med. 2014 Mar 29. [Epub ahead of print]. Transcatheter Aortic valve replacement (TAVR) with balloon expandable valve showed survival improvement in inoperable patients and was similar to surgery inoperable high-risk patients. An alternative to the above device is the self-expandable<a href="https://solaci.org/en/2014/04/09/core-valve-in-high-risk-patients-superior-to-surgical-replacement-at-one-year/" title="Read more" >...</a>
Original title: Reduction of pacemaker implantation rates alter CoreValve implantation by moderate predilatation Reference: Philipp Lange, et al. EuroIntervention 2014;9:1151-1159 Aortic valve implantation has been proven a valid strategy to treat high risk patients. The CoreValve self-expanding transcatheter aortic valve is associated with a relatively high rate of permanent pacemaker implantation and, until now, no efforts have been<a href="https://solaci.org/en/2014/03/05/predilation-with-smaller-valvuloplasty-balloon-diameter-could-reduce-the-need-for-permanent-pacemaker-after-corevalve/" title="Read more" >...</a>
Mitral annulus calcification (MAC) affects between 8% and 23% of the population. It is more common in women and patients with renal insufficiency. This phenomenon is characterized by an increase in valvular annulus fibrosis, which can extend and affect the leaflets. The presence of MAC is associated with valve regurgitation or stenosis, increasing mortality and<a href="https://solaci.org/en/2024/07/18/myocardial-damage-in-mac/" title="Read more" >...</a>